AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (4.4 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Propofol and salvianolic acid A synergistically attenuated cardiac ischemia–reperfusion injury in diabetic mice via modulating the CD36/AMPK pathway

Jiaqi Zhou1,2,†, Weiyi Xia1,3,†, Jiajia Chen1,†, Kaijia Han1, Yuxin Jiang1, Anyuan Zhang4, Dongcheng Zhou1, Danyong Liu1, Jiefu Lin1, Yin Cai1,5, Guanghua Chen6, Liangqing Zhang1, Aimin Xu2, Youhua Xu7,‡, Ronghui Han1,7,‡( ), Zhengyuan Xia1,2,‡ ( )
Department of Anesthesiology, Affiliated Hospital of Guangdong Medical University, No. 57, South Renmin Avenue, Zhanjiang, 524000, China
State Key Laboratory of Pharmaceutical Biotechnology, Department of Medicine, The University of Hong Kong, Pok Fu Lam Road, Hong Kong, 999077, China
Department of Orthopaedics and Traumatology, The University of Hong Kong, Pok Fu Lam Road, Hong Kong, 999077, China
Department of Anesthesiology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, No. 109 Xueyuan West Road, Wenzhou, Zhejiang, 325027, China
Department of Health Technology and Informatics, The Hong Kong Polytechnic University, No. 11 Yucai Road, hung hom, Kowloon, Hong Kong, 999077, China
Spinal Division of Orthopedic and Traumatology Center, The Affiliated Hospital of Guangdong Medical University, No. 57 South Renmin Avenue, Zhanjiang 524000, China
Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida WaiLong, Taipa, Macao, 999078, China

†Jiaqi Zhou, Weiyi Xia and Jiajia Chen contributed equally to this work.

‡Youhua Xu, Ronghui Han and Zhengyuan Xia share senior authorship.

Show Author Information

Highlights

• A combination of propofol and salvianolic acid A conferred synergistic protective effects against myocardial ischemia–reperfusion injury in diabetes.

• Inhibition of myocardial ischemia–reperfusion injury-induced increase in ferroptosis may represent a major mechanism whereby propofol and salvianolic acid A confer cardioprotection in diabetes.

• Propofol combined with salvianolic acid A activated AMPK through inhibiting CD36 under diabetic condition, leading to reduced ferroptosis and cardiomyocyte hypoxia/reoxygenation injury.

• The combined application of low-dose propofol and salvianolic acid A to achieve superior cardioprotection to the use of high-dose propofol may effectively avoid hemodynamic instability while increasing its antioxidant properties, which may have significant clinical implications.

Abstract

Background

Prevention of diabetic heart myocardial ischemia–reperfusion (IR) injury (MIRI) is challenging. Propofol attenuates MIRI through its reactive oxygen species scavenging property at high doses, while its use at high doses causes hemodynamic instability. Salvianolic acid A (SAA) is a potent antioxidant that confers protection against MIRI. Both propofol and SAA affect metabolic profiles through regulating Adenosine 5‘-monophosphate-activated protein kinase (AMPK). The aim of this study was to investigate the protective effects and underlying mechanisms of low doses of propofol combined with SAA against diabetic MIRI.

Methods

Diabetes was induced in mice by a high-fat diet followed by streptozotocin injection, and MIRI was induced by coronary artery occlusion and reperfusion. Mice were treated with propofol at 46 mg/kg/h without or with SAA at 10 mg/kg/h during IR. Cardiac origin H9c2 cells were exposed to high glucose (HG) and palmitic acid (PAL) for 24 h in the absence or presence of cluster of differentiation 36 (CD36) overexpression or AMPK gene knockdown, followed by hypoxia/reoxygenation (HR) for 6 and 12 h.

Results

Diabetes-exacerbated MIRI is evidenced as significant increases in post-ischemic infarction with reductions in phosphorylated (p)-AMPK and increases in CD36 and ferroptosis. Propofol moderately yet significantly attenuated all the abovementioned changes, while propofol plus SAA conferred superior protection against MIRI to that of propofol. In vitro, exposure of H9c2 cells under HG and PAL decreased cell viability and increased oxidative stress that was concomitant with increased levels of ferroptosis and a significant increase in CD36, while p-AMPK was significantly reduced. Co-administration of low concentrations of propofol and SAA at 12.5 μM in H9c2 cells significantly reduced oxidative stress, ferroptosis and CD36 expression, while increasing p-AMPK compared to the effects of propofol at 25 μM. Moreover, either CD36 overexpression or AMPK silence significantly exacerbated HR-induced cellular injuries and ferroptosis, and canceled propofol- and SAA-mediated protection. Notably, p-AMPK expression was downregulated after CD36 overexpression, while AMPK knockdown did not affect CD36 expression.

Conclusions

Combinational usage of propofol and SAA confers superior cellular protective effects to the use of high-dose propofol alone, and it does so through inhibiting HR-induced CD36 overexpression to upregulate p-AMPK.

References

【1】
【1】
 
 
Burns & Trauma
Article number: tkad055

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Zhou J, Xia W, Chen J, et al. Propofol and salvianolic acid A synergistically attenuated cardiac ischemia–reperfusion injury in diabetic mice via modulating the CD36/AMPK pathway. Burns & Trauma, 2024, 12: tkad055. https://doi.org/10.1093/burnst/tkad055

5

Views

0

Downloads

0

Crossref

0

Web of Science

30

Scopus

Received: 19 March 2023
Revised: 14 October 2023
Accepted: 14 October 2023
Published: 10 October 2026
© The Author(s) 2024. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com